Patients with relapsed/refractory myeloma from lower socioeconomic groups face worse quality of life, even in countries with universal health care, according to Francesco Sparano, MSc, of the Italian-based GIMEMA Foundation.
Francesco Sparano, MSc
Advertisement
Articles by Francesco Sparano, MSc
Patients with relapsed/refractory (R/R) multiple myeloma and lower socioeconomic status reported significantly worse quality of life and a higher burden of symptoms, according to Francesco Sparano, MSc, of the GIMEMA Foundation.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Dual JAK Inhibition Demonstrates Efficacy in Progressive Nonsegmental Vitiligo
2
FDA Approves Guselkumab for Pediatric Plaque Psoriasis, Active Psoriatic Arthritis
3
Nerandomilast a "No-Brainer" for First-Line Pulmonary Fibrosis Therapy: Justin M. Oldham, MD, PhD, MS
4
FDA Grants Breakthrough Therapy Designation to R-DXd in CDH6-Expressing Ovarian Cancer
5
